JP7740706B2 - 多能性幹細胞の胸腺上皮細胞および胸腺上皮前駆細胞分化を促進する方法 - Google Patents

多能性幹細胞の胸腺上皮細胞および胸腺上皮前駆細胞分化を促進する方法

Info

Publication number
JP7740706B2
JP7740706B2 JP2021558816A JP2021558816A JP7740706B2 JP 7740706 B2 JP7740706 B2 JP 7740706B2 JP 2021558816 A JP2021558816 A JP 2021558816A JP 2021558816 A JP2021558816 A JP 2021558816A JP 7740706 B2 JP7740706 B2 JP 7740706B2
Authority
JP
Japan
Prior art keywords
cells
human
pharyngeal
thymic
endoderm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021558816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527338A (ja
Inventor
ペナ，ラファエル グラス
サイクス，メーガン
ダンツル，ニコル
コスラヴィ‐マハールーイ，モーゼン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University
Original Assignee
Columbia University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University filed Critical Columbia University
Publication of JP2022527338A publication Critical patent/JP2022527338A/ja
Priority to JP2024121246A priority Critical patent/JP2024153768A/ja
Application granted granted Critical
Publication of JP7740706B2 publication Critical patent/JP7740706B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/065—Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2021558816A 2019-04-01 2020-03-31 多能性幹細胞の胸腺上皮細胞および胸腺上皮前駆細胞分化を促進する方法 Active JP7740706B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024121246A JP2024153768A (ja) 2019-04-01 2024-07-26 多能性幹細胞の胸腺上皮細胞および胸腺上皮前駆細胞分化を促進する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962827383P 2019-04-01 2019-04-01
US62/827,383 2019-04-01
PCT/US2020/025955 WO2020205859A1 (en) 2019-04-01 2020-03-31 Methods of promoting thymic epithelial cell and thymic epithelial cell progenitor differentiation of pluripotent stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024121246A Division JP2024153768A (ja) 2019-04-01 2024-07-26 多能性幹細胞の胸腺上皮細胞および胸腺上皮前駆細胞分化を促進する方法

Publications (2)

Publication Number Publication Date
JP2022527338A JP2022527338A (ja) 2022-06-01
JP7740706B2 true JP7740706B2 (ja) 2025-09-17

Family

ID=72667458

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021558816A Active JP7740706B2 (ja) 2019-04-01 2020-03-31 多能性幹細胞の胸腺上皮細胞および胸腺上皮前駆細胞分化を促進する方法
JP2024121246A Pending JP2024153768A (ja) 2019-04-01 2024-07-26 多能性幹細胞の胸腺上皮細胞および胸腺上皮前駆細胞分化を促進する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024121246A Pending JP2024153768A (ja) 2019-04-01 2024-07-26 多能性幹細胞の胸腺上皮細胞および胸腺上皮前駆細胞分化を促進する方法

Country Status (11)

Country Link
US (1) US20220127569A1 (cg-RX-API-DMAC7.html)
EP (1) EP3947639A4 (cg-RX-API-DMAC7.html)
JP (2) JP7740706B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210146297A (cg-RX-API-DMAC7.html)
CN (2) CN113646423B (cg-RX-API-DMAC7.html)
AU (1) AU2020253429B2 (cg-RX-API-DMAC7.html)
CA (1) CA3135377A1 (cg-RX-API-DMAC7.html)
IL (1) IL286936A (cg-RX-API-DMAC7.html)
MX (1) MX2021012041A (cg-RX-API-DMAC7.html)
SG (1) SG11202109279PA (cg-RX-API-DMAC7.html)
WO (1) WO2020205859A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4142754A4 (en) * 2020-04-28 2024-06-12 The Regents Of The University Of California METHODS FOR IN VITRO GENERATION OF THYMIC CELLS
US20240076618A1 (en) * 2021-01-15 2024-03-07 The Board Of Trustees Of The Leland Stanford Junior University Generation of induced human thymic epithelial cells and its application in cell-based immunotherapies
CN113215081B (zh) * 2021-06-01 2023-04-14 华中科技大学同济医学院附属同济医院 诱导干细胞分化为甲状旁腺细胞的方法及其组合物
KR20240075885A (ko) * 2021-10-15 2024-05-29 타이뮨 테라퓨틱스, 인코포레이티드 가슴샘 세포 및 제조 방법
EP4293110A1 (en) 2022-06-17 2023-12-20 Nantes Université Process for obtaining functional lymphocytes cells
WO2025136749A1 (en) * 2023-12-19 2025-06-26 The Board Of Trustees Of The Leland Stanford Junior University Thymic epithelial cells and methods of producing and using the same
CN119614476B (zh) * 2024-11-13 2026-05-15 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 胸腺类器官的构建方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004516834A (ja) 2000-12-22 2004-06-10 ユニヴァーシティー オブ エディンバラ 胸腺上皮前駆細胞およびその使用
JP2013524836A (ja) 2010-04-25 2013-06-20 マウント・シナイ・スクール・オブ・メディスン 多能性細胞からの前部前腸内胚葉の生成

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010143529A1 (ja) * 2009-06-09 2010-12-16 国立大学法人名古屋大学 多能性幹細胞を胸腺上皮へ分化誘導する方法
CN102732479B (zh) * 2011-03-31 2014-08-27 北京大学 胸腺上皮前体细胞的制备方法及其专用培养基
US9657273B2 (en) * 2012-10-12 2017-05-23 Industry-University Cooperation Foundation Sogang University Method for suppressing teratoma formation via selective cell death induction in undifferentiated human-induced pluripotent stem cells
WO2014134213A1 (en) 2013-02-27 2014-09-04 The Regents Of The University Of California Generation of thymic epithelial progenitor cells in vitro
WO2019060336A1 (en) 2017-09-20 2019-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IN VITRO GENERATION OF THYMIC ORGANOID FROM HUMAN PLURIPOTENT STEM CELLS
EP3959304A4 (en) * 2019-04-26 2023-01-25 The Regents Of The University Of Colorado, A Body Corporate GENERATION OF FUNCTIONAL AND PATIENT-SPECIFIC THYMUS TISSUE IN VIVO FROM INDUCED PLURIPOTENTS STEM CELLS
CA3159010A1 (en) * 2019-11-25 2021-06-03 Yong Fan Thymus organoids bioengineered form human pluripotent stem cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004516834A (ja) 2000-12-22 2004-06-10 ユニヴァーシティー オブ エディンバラ 胸腺上皮前駆細胞およびその使用
JP2013524836A (ja) 2010-04-25 2013-06-20 マウント・シナイ・スクール・オブ・メディスン 多能性細胞からの前部前腸内胚葉の生成

Also Published As

Publication number Publication date
AU2020253429A1 (en) 2021-09-09
EP3947639A1 (en) 2022-02-09
EP3947639A4 (en) 2023-01-25
AU2020253429B2 (en) 2026-05-28
IL286936A (en) 2021-10-31
CN113646423A (zh) 2021-11-12
KR20210146297A (ko) 2021-12-03
JP2024153768A (ja) 2024-10-29
WO2020205859A1 (en) 2020-10-08
CN119351306A (zh) 2025-01-24
CN113646423B (zh) 2024-10-01
SG11202109279PA (en) 2021-09-29
JP2022527338A (ja) 2022-06-01
CA3135377A1 (en) 2020-10-08
MX2021012041A (es) 2021-11-03
US20220127569A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
CN113646423B (zh) 促进多能干细胞的胸腺上皮细胞和胸腺上皮细胞祖细胞的分化的方法
AU2009200256B2 (en) Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US20070082397A1 (en) Ex vivo progenitor and stem cell expansion for use in the treatment of disease of endodermally-derived organs
TW201815399A (zh) 利用血管母細胞產生間葉基質細胞之方法
KR20220000930A (ko) 다능성 줄기세포로부터 간세포 및 담관세포의 생성 방법
MXPA04009997A (es) Modulacion de la diferenciacion de celulas madre y progenitoras, ensayos y usos de las mismas.
Tsuneyoshi et al. Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity
WO2020220040A1 (en) Generation of functional and patient-specific thymic tissue in vivo from induced pluripotent stem cells
US20190352601A1 (en) Engineering blood vessel cells for transplantation
US20230332107A1 (en) Cell therapy for diabetes
Lombard et al. Human Hepatocytes and Differentiated Adult‐Derived Human Liver Stem/Progenitor Cells Display In Vitro Immunosuppressive Properties Mediated, at Least in Part, through the Nonclassical HLA Class I Molecule HLA‐G
CA2679178A1 (en) Compositions and methods for treating peripheral vascular diseases
US20040096971A1 (en) Thymic epithelial progenitor cells and uses thereof
KR20240075885A (ko) 가슴샘 세포 및 제조 방법
US20230346841A1 (en) Compositions, methods and uses for in vitro and in vivo generation of functional thymic tissue
Hosaka et al. Induction of γδT cells from HSC‐enriched BMCs co‐cultured with iPSC‐derived thymic epithelial cells
AU2012200787C1 (en) Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CN101083910B (zh) 用于预防和治疗移植中的免疫应答的肝脏基质细胞
Arriola iPSC-derived Intestinal Organoids Modeling Development and Disease
Tysoe The Immunogenicity of Cholangiocyte Cellular Therapies
Torabi In utero stem cell transplantation: Induction of tolerance and generation of donor-derived hepatocytes
Genead Embryonic and adult cardiac stem cells-molecular, electrophysical and immunological characteristics for cardiac repair
Genead Department of Medicine Huddinge, Division of Cardiology Karolinska Institutet, Stockholm, Sweden
WO2008104065A1 (en) Neural cell preparations and methods of making and using them
HK1164370A (en) Modulation of stem and progenitor cell differentiation, assays, and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250520

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250729

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250828

R150 Certificate of patent or registration of utility model

Ref document number: 7740706

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150